A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia

Leukemia Research

Volumn 33, Issue 8, 2009, Pages 1055-1061

  Lancet, Jeffrey E ^a   Baer, Maria R ^b   Duran, George E ^d   List, Alan F ^a   Fielding, Robert ^c   Marcelletti, John F ^c   Multani, Pratik S ^c   Sikic, Branimir I ^d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c Kanisa Pharmaceuticals Inc   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Multidrug resistance; P glycoprotein; Zosuquidar

Indexed keywords

CYTARABINE; DAUNORUBICIN; GLYCOPROTEIN P; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; AREA UNDER THE CURVE; ARTICLE; BLAST CELL; CANCER PATIENT; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DELIRIUM; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HUMAN TISSUE; HYPOKALEMIA; INFECTION; LEUKEMIA CELL; MALE; MAXIMUM PLASMA CONCENTRATION; NATURAL KILLER CELL; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; DIBENZOCYCLOHEPTENES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; P-GLYCOPROTEIN; QUINOLINES; TIME FACTORS;

EID: 67349183943     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.09.015     Document Type: Article

References (35)

1. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 107 (2006) 3481-3485
2. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98 (2001) 1312-1320
3. Kantarjian H., O'Brien S., Cortes J., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106 (2006) 1090-1098
4. Leith C.P., Kopecky K.J., Godwin J., et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89 (1997) 3323-3329
5. Godwin J.E., Kopecky K.J., Head D.R., et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 91 (1998) 3607-3615
6. Lowenberg B., Suciu S., Archimbaud E., et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 16 (1998) 872-881
7. Rowe J.M., Neuberg D., Friedenberg W., et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 103 (2004) 479-485
8. Mahadevan D., and List A.F. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 104 (2004) 1940-1951
9. Campos L., Guyotat D., Archimbaud E., et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79 (1992) 473-476
10. List A.F., Kopecky K.J., Willman C.L., et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98 (2001) 3212-3220
11. Marie J.P., Zittoun R., and Sikic B.I. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78 (1991) 586-592
12. Samdani A., Vijapurkar U., Grimm M.A., et al. Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leuk Res 20 (1996) 175-180
13. van der Holt B., Lowenberg B., Burnett A.K., et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106 (2005) 2646-2654
14. Advani R., Saba H.I., Tallman M.S., et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93 (1999) 787-795
15. Baer M.R., George S.L., Dodge R.K., et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100 (2002) 1224-1232
16. Liu Yin J.A., Wheatley K., Rees J.K., and Burnett A.K. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 113 (2001) 713-726
17. Solary E., Drenou B., Campos L., et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 102 August 15 (2003) 1202-1210
18. Solary E., Witz B., Caillot D., et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 88 (1996) 1198-1205
19. Matsouka P., Pagoni M., Zikos P., et al. Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology. Ann Hematol 85 (2006) 250-256
20. Wattel E., Solary E., Hecquet B., et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol 102 (1998) 1015-1024
21. Wattel E., Solary E., Hecquet B., et al. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Francais des Myelodysplasies (GFM) and Groupe GOELAMS. Adv Exp Med Biol 457 (1999) 35-46
22. Greenberg P.L., Lee S.J., Advani R., et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 22 (2004) 1078-1086
23. Dantzig A.H., Shepard R.L., Cao J., et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56 (1996) 4171-4179
24. Dantzig A.H., Shepard R.L., Law K.L., et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 290 (1999) 854-862
25. Gerrard G., Payne E., Baker R.J., et al. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 89 (2004) 782-790
26. Green L.J., Marder P., and Slapak C.A. Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem Pharmacol 61 (2001) 1393-1399
27. Rubin E.H., de Alwis D.P., Pouliquen I., et al. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 8 (2002) 3710-3717
28. Sandler A., Gordon M., De Alwis D.P., et al. A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 10 (2004) 3265-3272
29. Shepard R.L., Cao J., Starling J.J., and Dantzig A.H. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 103 (2003) 121-125
30. Starling J.J., Shepard R.L., Cao J., et al. Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv Enzyme Regul 37 (1997) 335-347
31. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
32. Harker W.G., and Sikic B.I. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 45 (1985) 4091-4096
33. Cheson B.D., Cassileth P.A., Head D.R., et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8 (1990) 813-819
34. Callies S., de Alwis D.P., Mehta A., Burgess M., and Aarons L. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar. 3HCl (LY335979). Cancer Chemother Pharmacol 54 (2004) 39-48
35. Stelzer G.T., Shults K.E., and Loken M.R. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci 677 (1993) 265-280